The DOI matches its Crossref record; 102 of the 102 references it cites were found in a registry or an index.
The past, present, and future of antibiotics
Abstract
Antibiotics have transformed modern medicine. They are essential for treating infectious diseases and enable vital therapies and procedures. However, despite this success, their continued use in the 21st century is imperiled by two orthogonal challenges. The first is that the microbes targeted by these drugs evolve resistance to them over time. The second is that antibiotic discovery and development are no longer cost-effective using traditional reimbursement models. Consequently, there are a dwindling number of companies and laboratories dedicated to delivering new antibiotics, resulting in an anemic pipeline that threatens our control of infections. The future of antibiotics requires innovation in a field that has relied on highly traditional methods of discovery and development. This will require substantial changes in policy, quantitative understanding of the societal value of these drugs, and investment in alternatives to traditional antibiotics. These include narrow-spectrum drugs, bacteriophage, monoclonal antibodies, and vaccines, coupled with highly effective diagnostics. Addressing the antibiotic crisis to meet our future needs requires considerable investment in both research and development, along with ensuring a viable marketplace that encourages innovation. This review explores the past, present, and future of antimicrobial therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis
Murray, C. J. L., Ikuta, K. S., Sharara, F., Swetschinski, L., Robles Aguilar, G., Gray, A., Han, C., Bisignano, C., Rao, P., Wool, E., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(21)02724-0 · Cited by 16,316
Magiorakos, A.-P., Srinivasan, A., Carey, R. B., Carmeli, Y., Falagas, M. E., Giske, C. G., Harbarth, S., Hindler, J. F., Kahlmeter, G., Olsson-Liljequist, B., et al. (2012) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2011.03570.x · Cited by 14,449
Prokaryotes: The unseen majority
Whitman, W. B., Coleman, D. C., & Wiebe, W. J. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.12.6578 · Cited by 4,871
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3078 · Cited by 3,566
Innovation in the pharmaceutical industry: New estimates of R&D costs
DiMasi, J. A., Grabowski, H. G., & Hansen, R. W. (2016) · Journal of Health Economics · doi:10.1016/j.jhealeco.2016.01.012 · Cited by 3,359
Acinetobacter baumannii : Emergence of a Successful Pathogen
Peleg, A. Y., Seifert, H., & Paterson, D. L. (2008) · Clinical Microbiology Reviews · doi:10.1128/cmr.00058-07 · Cited by 3,316
Drugs for bad bugs: confronting the challenges of antibacterial discovery
Payne, D. J., Gwynn, M. N., Holmes, D. J., & Pompliano, D. L. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2201 · Cited by 2,512
A Deep Learning Approach to Antibiotic Discovery
Stokes, J. M., Yang, K., Swanson, K., Jin, W., Cubillos-Ruiz, A., Donghia, N. M., MacNair, C. R., French, S., Carfrae, L. A., Bloom-Ackermann, Z., et al. (2020) · Cell · doi:10.1016/j.cell.2020.01.021 · Cited by 2,463
A new antibiotic kills pathogens without detectable resistance
Ling, L. L., Schneider, T., Peoples, A. J., Spoering, A. L., Engels, I., Conlon, B. P., Mueller, A., Schäberle, T. F., Hughes, D. E., Epstein, S., et al. (2015) · Nature · doi:10.1038/nature14098 · Cited by 2,428
Development of therapeutic antibodies for the treatment of diseases
Lu, R.-M., Hwang, Y.-C., Liu, I.-J., Lee, C.-C., Tsai, H.-Z., Li, H.-J., & Wu, H.-C. (2020) · Journal of Biomedical Science · doi:10.1186/s12929-019-0592-z · Cited by 2,085
Probiotics and prebiotics in intestinal health and disease: from biology to the clinic
Sanders, M. E., Merenstein, D. J., Reid, G., Gibson, G. R., & Rastall, R. A. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0173-3 · Cited by 2,059
Antimicrobial host defence peptides: functions and clinical potential
Mookherjee, N., Anderson, M. A., Haagsman, H. P., & Davidson, D. J. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0058-8 · Cited by 1,502
Ten Great Public Health Achievements—United States, 1900-1999
(1999) · JAMA · doi:10.1001/jama.281.16.1481 · Cited by 1,298
Unlocking the potential of antibody–drug conjugates for cancer therapy
Drago, J. Z., Modi, S., & Chandarlapaty, S. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00470-8 · Cited by 1,150
Phage therapy: An alternative to antibiotics in the age of multi-drug resistance
Lin, D. M., Koskella, B., & Lin, H. C. (2017) · World Journal of Gastrointestinal Pharmacology and Therapeutics · doi:10.4292/wjgpt.v8.i3.162 · Cited by 1,135
Trends in Infectious Disease Mortality in the United States During the 20th Century
Armstrong, G. L. (1999) · JAMA · doi:10.1001/jama.281.1.61 · Cited by 875
Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection
Wilcox, M. H., Gerding, D. N., Poxton, I. R., Kelly, C., Nathan, R., Birch, T., Cornely, O. A., Rahav, G., Bouza, E., Lee, C., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1602615 · Cited by 858
Monoclonal Antibodies in Cancer Therapy
Zahavi, D., & Weiner, L. (2020) · Antibodies · doi:10.3390/antib9030034 · Cited by 831
A new antibiotic selectively kills Gram-negative pathogens
Imai, Y., Meyer, K. J., Iinishi, A., Favre-Godal, Q., Green, R., Manuse, S., Caboni, M., Mori, M., Niles, S., Ghiglieri, M., et al. (2019) · Nature · doi:10.1038/s41586-019-1791-1 · Cited by 743
Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children
Goldenberg, J. Z., Ma, S. S., Saxton, J. D., Martzen, M. R., Vandvik, P. O., Thorlund, K., Guyatt, G. H., & Johnston, B. C. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006095.pub3 · Cited by 741
The global preclinical antibacterial pipeline
Theuretzbacher, U., Outterson, K., Engel, A., & Karlén, A. (2020) · Nature Reviews Microbiology · doi:10.1038/s41579-019-0288-0 · Cited by 738
Physicochemical Properties of Antibacterial Compounds: Implications for Drug Discovery
O’Shea, R., & Moser, H. E. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm700967e · Cited by 689
ESKAPEing the labyrinth of antibacterial discovery
Tommasi, R., Brown, D. G., Walkup, G. K., Manchester, J. I., & Miller, A. A. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4572 · Cited by 608
Antibiotic Adjuvants: Rescuing Antibiotics from Resistance
Wright, G. D. (2016) · Trends in Microbiology · doi:10.1016/j.tim.2016.06.009 · Cited by 604
Self-citationMultidrug-resistant bacterial infections in U.S. hospitalized patients, 2012-2017.
Jernigan, J. A., Hatfield, K. M., Wolford, H., Nelson, R. E., Olubajo, B., Reddy, S. C., McCarthy, N., Paul, P., McDonald, L. C., Kallen, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1914433 · Cited by 577
Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children
Goldenberg, J. Z., Yap, C., Lytvyn, L., Lo, C. K.-F., Beardsley, J., Mertz, D., & Johnston, B. C. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006095.pub4 · Cited by 550
Combinations of antibiotics and nonantibiotic drugs enhance antimicrobial efficacy
Ejim, L., Farha, M. A., Falconer, S. B., Wildenhain, J., Coombes, B. K., Tyers, M., Brown, E. D., & Wright, G. D. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.559 · Cited by 525
Self-citationFDA approves 100th monoclonal antibody product
Mullard, A. (2021) · Nature Reviews Drug Discovery · doi:10.1038/d41573-021-00079-7 · Cited by 503
Effect of tolerance on the evolution of antibiotic resistance under drug combinations
Liu, J., Gefen, O., Ronin, I., Bar-Meir, M., & Balaban, N. Q. (2020) · Science · doi:10.1126/science.aay3041 · Cited by 485
Antibiotic development — economic, regulatory and societal challenges
Årdal, C., Balasegaram, M., Laxminarayan, R., McAdams, D., Outterson, K., Rex, J. H., & Sumpradit, N. (2020) · Nature Reviews Microbiology · doi:10.1038/s41579-019-0293-3 · Cited by 458
Review: Lessons Learned From Clinical Trials Using Antimicrobial Peptides (AMPs)
Dijksteel, G. S., Ulrich, M. M. W., Middelkoop, E., & Boekema, B. K. H. L. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.616979 · Cited by 428
The natural history of antibiotics
Clardy, J., Fischbach, M. A., & Currie, C. R. (2009) · Current Biology · doi:10.1016/j.cub.2009.04.001 · Cited by 402
DRAMP 2.0, an updated data repository of antimicrobial peptides
Kang, X., Dong, F., Shi, C., Liu, S., Sun, J., Chen, J., Li, H., Xu, H., Lao, X., & Zheng, H. (2019) · Scientific Data · doi:10.1038/s41597-019-0154-y · Cited by 393
Engineering living therapeutics with synthetic biology
Cubillos-Ruiz, A., Guo, T., Sokolovska, A., Miller, P. F., Collins, J. J., Lu, T. K., & Lora, J. M. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00285-3 · Cited by 356
Stokes, J. M., MacNair, C. R., Ilyas, B., French, S., Côté, J.-P., Bouwman, C., Farha, M. A., Sieron, A. O., Whitfield, C., Coombes, B. K., et al. (2017) · Nature Microbiology · doi:10.1038/nmicrobiol.2017.28 · Cited by 340
Classifying antibiotics in the WHO essential medicines list for optimal use—be AWaRe
Sharland, M., Pulcini, C., Harbarth, S., Zeng, M., Gandra, S., Mathur, S., & Magrini, N. (2018) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30724-7 · Cited by 336
Bispecific Antibodies: From Research to Clinical Application
Ma, J., Mo, Y., Tang, M., Shen, J., Qi, Y., Zhao, W., Huang, Y., Xu, Y., & Qian, C. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.626616 · Cited by 305
Yun, J., Lee, S.-H., Kim, S.-Y., Jeong, S.-Y., Kim, J.-H., Pyo, K.-H., Park, C.-W., Heo, S. G., Yun, M. R., Lim, S., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0116 · Cited by 297
Raxibacumab for the Treatment of Inhalational Anthrax
Migone, T.-S., Subramanian, G. M., Zhong, J., Healey, L. M., Corey, A., Devalaraja, M., Lo, L., Ullrich, S., Zimmerman, J., Chen, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810603 · Cited by 294
Evolution-guided discovery of antibiotics that inhibit peptidoglycan remodelling
Culp, E. J., Waglechner, N., Wang, W., Fiebig-Comyn, A. A., Hsu, Y.-P., Koteva, K., Sychantha, D., Coombes, B. K., Van Nieuwenhze, M. S., Brun, Y. V., et al. (2020) · Nature · doi:10.1038/s41586-020-1990-9 · Cited by 290
Self-citationA multifunctional bispecific antibody protects against Pseudomonas aeruginosa
DiGiandomenico, A., Keller, A. E., Gao, C., Rainey, G. J., Warrener, P., Camara, M. M., Bonnell, J., Fleming, R., Bezabeh, B., Dimasi, N., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3009655 · Cited by 277
Role of Protein A in the Evasion of Host Adaptive Immune Responses by Staphylococcus aureus
Falugi, F., Kim, H. K., Missiakas, D. M., & Schneewind, O. (2013) · mBio · doi:10.1128/mbio.00575-13 · Cited by 277
Recover the lost art of drug discovery
Lewis, K. (2012) · Nature · doi:10.1038/485439a · Cited by 276
Montassier, E., Valdés-Mas, R., Batard, E., Zmora, N., Dori-Bachash, M., Suez, J., & Elinav, E. (2021) · Nature Microbiology · doi:10.1038/s41564-021-00920-0 · Cited by 256
A synthetic antibiotic class overcoming bacterial multidrug resistance
Mitcheltree, M. J., Pisipati, A., Syroegin, E. A., Silvestre, K. J., Klepacki, D., Mason, J. D., Terwilliger, D. W., Testolin, G., Pote, A. R., Wu, K. J. Y., et al. (2021) · Nature · doi:10.1038/s41586-021-04045-6 · Cited by 239
The urgent need for metallo-β-lactamase inhibitors: an unattended global threat
Mojica, M. F., Rossi, M.-A., Vila, A. J., & Bonomo, R. A. (2022) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30868-9 · Cited by 230
Helping Chemists Discover New Antibiotics
Blaskovich, M. A. T., Zuegg, J., Elliott, A. G., & Cooper, M. A. (2015) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.5b00044 · Cited by 229
The challenge of converting Gram‐positive‐only compounds into broad‐spectrum antibiotics
Richter, M. F., & Hergenrother, P. J. (2019) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13598 · Cited by 227
Solomkin, J. S., Gardovskis, J., Lawrence, K., Montravers, P., Sway, A., Evans, D., & Tsai, L. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciy1029 · Cited by 222
Once-Daily Plazomicin for Complicated Urinary Tract Infections
Wagenlehner, F. M. E., Cloutier, D. J., Komirenko, A. S., Cebrik, D. S., Krause, K. M., Keepers, T. R., Connolly, L. E., Miller, L. G., Friedland, I., & Dwyer, J. P. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1801467 · Cited by 218
Inhibition of WTA Synthesis Blocks the Cooperative Action of PBPs and Sensitizes MRSA to β-Lactams
Farha, M. A., Leung, A., Sewell, E. W., D’Elia, M. A., Allison, S. E., Ejim, L., Pereira, P. M., Pinho, M. G., Wright, G. D., & Brown, E. D. (2013) · ACS Chemical Biology · doi:10.1021/cb300413m · Cited by 216
Self-citation(2021) · doi:10.3322/caac.21697 · Cited by 201
Dedrick, R. M., Freeman, K. G., Nguyen, J. A., Bahadirli-Talbott, A., Smith, B. E., Wu, A. E., Ong, A. S., Lin, C. T., Ruppel, L. C., Parrish, N. M., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01403-9 · Cited by 200
Acinetobacter baumannii Skin and Soft‐Tissue Infection Associated with War Trauma
Sebeny, P. J., Riddle, M. S., & Petersen, K. (2008) · Clinical Infectious Diseases · doi:10.1086/590568 · Cited by 188
François, B., Luyt, C.-E., Dugard, A., Wolff, M., Diehl, J.-L., Jaber, S., Forel, J.-M., Garot, D., Kipnis, E., Mebazaa, A., et al. (2012) · Critical Care Medicine · doi:10.1097/ccm.0b013e31825334f6 · Cited by 181
Biology of antimicrobial resistance and approaches to combat it
Schrader, S. M., Vaubourgeix, J., & Nathan, C. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aaz6992 · Cited by 173
Lehár, J., Stockwell, B. R., Giaever, G., & Nislow, C. (2008) · Nature Chemical Biology · doi:10.1038/nchembio.120 · Cited by 172
Abdelkader, K., Gerstmans, H., Saafan, A., Dishisha, T., & Briers, Y. (2019) · Viruses · doi:10.3390/v11020096 · Cited by 172
Jain, M., Ramirez, D., SESHADRI, R. M., Cullina, J. F., Powers, C. A., Schulert, G. S., Bar‐Meir, M., Sullivan, C., McColley, S. A., & Hauser, A. R. (2004) · Journal of Clinical Microbiology · doi:10.1128/jcm.42.11.5229-5237.2004 · Cited by 169
Genetic Engineering of Bacteriophages Against Infectious Diseases
Chen, Y., Batra, H., Dong, J., Chen, C., Rao, V. B., & Tao, P. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.00954 · Cited by 168
Bradford, P. A., Miller, A. A., O’Donnell, J. P., & Mueller, J. P. (2020) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.0c00021 · Cited by 163
DNA replication fidelity in Escherichia coli: a multi-DNA polymerase affair
Fijalkowska, I. J., Schaaper, R. M., & Jonczyk, P. (2012) · FEMS Microbiology Reviews · doi:10.1111/j.1574-6976.2012.00338.x · Cited by 162
Childhood vaccines and antibiotic use in low- and middle-income countries
Lewnard, J. A., Lo, N. C., Arinaminpathy, N., Frost, I., & Laxminarayan, R. (2020) · Nature · doi:10.1038/s41586-020-2238-4 · Cited by 162
Bacteriophages—a new hope or a huge problem in the food industry
Połaska, M., & Sokołowska, B. (2019) · AIMS Microbiology · doi:10.3934/microbiol.2019.4.324 · Cited by 155
Multi-species host range of staphylococcal phages isolated from wastewater
Göller, P. C., Elsener, T. A., Lorgé, D., Radulovic, N., Bernardi, V., Naumann, A., Amri, N., Khatchatourova, E., Coutinho, F. H., Loessner, M. J., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-27037-6 · Cited by 155
Tomczyk, S. M., Lynfield, R., Schaffner, W., Reingold, A. L., Miller, L. A., Petit, S., Holtzman, C., Zansky, S. M., Thomas, A. R., Baumbach, J., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw067 · Cited by 154
Karakonstantis, S., Kritsotakis, E. I., & Gikas, A. I. (2019) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkz401 · Cited by 150
Rational design of a new antibiotic class for drug-resistant infections
Durand-Réville, T. F., Miller, A. A., O’Donnell, J. P., Wu, X., Sylvester, M. A., Guler, S. Y., Iyer, R., Shapiro, A. B., Carter, N., Velez‐Vega, C., et al. (2021) · Nature · doi:10.1038/s41586-021-03899-0 · Cited by 138
A probiotic yeast-based immunotherapy against Clostridioides difficile infection
Chen, K., Zhu, Y., Zhang, Y., Hamza, T., Yu, H., Fleur, A. S., Galen, J. E., Yang, Z., & Feng, H. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aax4905 · Cited by 137
Prediction of Synergism from Chemical-Genetic Interactions by Machine Learning
Wildenhain, J., Spitzer, M., Dolma, S., Jarvik, N., White, R., Roy, M. M., Griffiths, E., Bellows, D. S., Wright, G. D., & Tyers, M. (2015) · Cell Systems · doi:10.1016/j.cels.2015.12.003 · Cited by 132
Self-citationFrançois, B., Mercier, E., Gonzalez, C., Asehnoune, K., Nseir, S., Fiancette, M., Desachy, A., Plantefève, G., Meziani, F., de Lame, P.-A., et al. (2018) · Intensive Care Medicine · doi:10.1007/s00134-018-5229-2 · Cited by 132
François, B., Jafri, H. S., Chastre, J. E., García, M. S., Eggimann, P., Dequin, P., Huberlant, V., Soria, L. V., Boulain, T., Bretonnière, C., et al. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30995-6 · Cited by 121
Peck, M. C., Rothenberg, M. E., Deng, R., Lewin‐Koh, N., She, G., Kamath, A. V., Carrasco‐Triguero, M., Saad, O. M., Castro, A., Teufel, L. U., et al. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02588-18 · Cited by 118
Jain, R., Beckett, V. V., Konstan, M. W., Accurso, F. J., Burns, J. L., Mayer-Hamblett, N., Milla, C. E., VanDevanter, D. R., & Chmiel, J. F. (2017) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2017.12.006 · Cited by 115
Receptor-targeted engineered probiotics mitigate lethal Listeria infection
Drolia, R., Amalaradjou, M. A. R., Ryan, V., Tenguria, S., Liu, D., Bai, X., Xu, L., Singh, A. K., Cox, A. D., Bernal-Crespo, V., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-20200-5 · Cited by 112
Development of a platform for the discovery and practical synthesis of new tetracycline antibiotics
Liu, F., & Myers, A. G. (2016) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2016.03.011 · Cited by 100
Shapiro, A. B., Moussa, S. H., McLeod, S. M., Durand-Réville, T. F., & Miller, A. A. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.709974 · Cited by 97
Advances in Bacteriophage Therapy against Relevant MultiDrug-Resistant Pathogens
Broncano-Lavado, A., Santamaría-Corral, G., Esteban, J., & García‐Quintanilla, M. (2021) · Antibiotics · doi:10.3390/antibiotics10060672 · Cited by 94
Discovery of Macrolide Antibiotics Effective against Multi-Drug Resistant Gram-Negative Pathogens
Myers, A. G., & Clark, R. B. (2021) · Accounts of Chemical Research · doi:10.1021/acs.accounts.1c00020 · Cited by 93
Cleavage of human immunoglobulins by serine proteinase from Staphylococcus aureus
Prokešová, L., Potuźníková, B., Potempa, J., Zikán, J., Radl, J., Hachová, L., Baran, K., Porwit-Bóbr, Z., & John, C. (1992) · Immunology Letters · doi:10.1016/0165-2478(92)90124-7 · Cited by 90
The impact of human vaccines on bacterial antimicrobial resistance. A review
Jansen, K. U., Gruber, W. C., Simon, R., Wassil, J., & Anderson, A. S. (2021) · Environmental Chemistry Letters · doi:10.1007/s10311-021-01274-z · Cited by 88
Heilmann, K. P., Rice, C., Miller, A. L., Miller, N. J., Beekmann, S. E., Pfaller, M. A., Richter, S. S., & Doern, G. V. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.6.2561-2564.2005 · Cited by 86
Goldstein, E. J. C., Citron, D. M., Tyrrell, K. L., & Merriam, C. V. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01136-13 · Cited by 82
Gepotidacin (GSK2140944) In Vitro Activity against Gram-Positive and Gram-Negative Bacteria
Flamm, R. K., Farrell, D. J., Rhomberg, P. R., et al. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00468-17 · Cited by 81
Aghaee, B. L., Mirzaei, M. K., Alikhani, M. Y., & Mojtahedi, A. (2021) · BMC Microbiology · doi:10.1186/s12866-021-02197-z · Cited by 73
A robust platform for chemical genomics in bacterial systems
French, S., Mangat, C. S., Bharat, A., Côté, J., Mori, H., & Brown, E. D. (2016) · Molecular Biology of the Cell · doi:10.1091/mbc.e15-08-0573 · Cited by 69
Cefiderocol: A New Cephalosporin Stratagem Against Multidrug-Resistant Gram-Negative Bacteria
Onguti, S. K., Czech, M. M., Robilotti, E. V., & Holubar, M. K. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab757 · Cited by 68
Barcudi, D., Sosa, E. J., Lamberghini, R. O., Garnero, A., Tosoroni, D., Decca, L., Gonzalez, L., Kuyuk, M. A., Lopez, T., Herrero, I., et al. (2019) · Journal of Infection · doi:10.1016/j.jinf.2019.10.001 · Cited by 62
Design and Syntheses of New Antibiotics Inspired by Nature’s Quest for Iron in an Oxidative Climate
Miller, M. J., & Liu, R. (2021) · Accounts of Chemical Research · doi:10.1021/acs.accounts.1c00004 · Cited by 58
Antibiotics: the changing regulatory and pharmaceutical industry paradigm
Bax, R. P., & Green, S. (2015) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dku572 · Cited by 52
Phages & Antibiotic Resistance: Are the Most Abundant Entities on Earth Ready for a Comeback?
Hill, C., Mills, S., & Ross, R. P. (2018) · Future Microbiology · doi:10.2217/fmb-2017-0261 · Cited by 52
Yamamoto, B., Shadiack, A. M., Carpenter, S., Sanford, D., Henning, L. N., Gonzales, N., O'Connor, E., Casey, L. S., & Serbina, N. V. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01102-16 · Cited by 49
Le, H. N., Quetz, J. D. S., Tran, V. G., Le, V. T. M., Aguiar-Alves, F., Pinheiro, M. G., Cheng, L., Yu, L., Sellman, B. R., Stover, C. K., et al. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02565-17 · Cited by 49
Lepak, A. J., Wang, W., & Andes, D. R. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01517-20 · Cited by 47
Davies, D. T., & Everett, M. J. (2021) · Accounts of Chemical Research · doi:10.1021/acs.accounts.0c00863 · Cited by 46
van Werkhoven, C. H., Ducher, A., Berkell, M., Mysara, M., Lammens, C., Torre‐Cisneros, J., Rodríguez‐Baño, J., Herghea, D., Cornely, O. A., Biehl, L. M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22269-y · Cited by 42
Colson, A. R., Morton, A., Årdal, C., Chalkidou, K., Davies, S. C., Garrison, L. P., Jit, M., Laxminarayan, R., Megiddo, I., Morel, C. M., et al. (2021) · Value in Health · doi:10.1016/j.jval.2021.06.002 · Cited by 35
Reinisch, W., Hébuterne, X., Buisson, A., Schreiber, S., Desreumaux, P., Primas, C., Paillarse, J.-M., Chevalier, G., & Bonny, C. (2022) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.15828 · Cited by 32
Antibacterial R&D at a Crossroads: We’ve Pushed as Hard as We Can … Now We Need to Start Pulling!
Rex, J. H., & Outterson, K. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa852 · Cited by 17
Aguiar-Alves, F., Le, H. N., Tran, V. G., Gras, E., Vu, T. T. T., Dong, O. X., Quetz, J. D. S., Cheng, L., Yu, L., Sellman, B. R., et al. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02022-21 · Cited by 16
Jester, B. W., Zhao, H., Gewe, M. M., Adame, T., Perruzza, L., Bolick, D. T., Agosti, J. M., Khuong, N., Kuestner, R. E., Gamble, C., et al. (2022) · Nature Biotechnology · doi:10.1038/s41587-022-01323-0 · Cited by 4
Cited by
Bacterial persisters: molecular mechanisms and therapeutic development
Niu, H., Gu, J., & Zhang, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01866-5 · Cited by 310
Nanozybiotics: advancing antimicrobial strategies through biomimetic mechanisms
Zhou, C., Wang, Q., Cao, H., Jiang, J., & Gao, L. (2024) · Advanced Materials · doi:10.1002/adma.202403362 · Cited by 114
Heavy metal co-resistance with antibiotics amongst bacteria isolates from an open dumpsite soil
Edet, U. O., Bassey, I. U., & Joseph, A. P. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e13457 · Cited by 42
Ghosh, S., Basu, S., Anbarasu, A., & Ramaiah, S. (2025) · Phytotherapy Research · doi:10.1002/ptr.8365 · Cited by 33
Wei, J., Liu, C., Qin, D., Ren, F., Duan, J., Chen, T., & Wu, A. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102544 · Cited by 15
Metadata
- Authors
- Cook, M. A., & Wright, G. D.
- Venue
- Science Translational Medicine
- Published
- 2022-08-10
- Volume
- 14
- Issue
- 657
- Pages
- eabo7793-eabo7793
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W4291020097
- Cited by
- 652
- References
- 102
- FWCI
- 48.22
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.